– USA, WA – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Dr. Karen Akinsanya (Ph.D.) to its Board of Directors, bringing more than 25 years of experience in drug discovery and development, commercialization, partnerships, and licensing from across academia and pharmaceutical research and development.
“Dr. Akinsanya’s proven leadership in realizing and strategically executing on the potential of high-impact clinical and translational programs as well as transformative technologies is unrivaled in the biopharmaceutical industry. We are excited to welcome her as the newest member of our board, expanding the breadth and depth of business and scientific acumen that will bolster our go-to-market and commercialization strategy for widening access and understanding of the human proteome to improve human health,” said co-founder and CEO, Sujal Patel.
About Dr. Karen Akinsanya
In her current role as President of R&D, Therapeutics at Schrödinger, Dr. Karen Akinsanya leads the company’s therapeutics group that leverages Schrödinger’s leading physics-based platform for preclinical drug discovery and is responsible for translational research and early development, in addition to business development and collaborations.
Before joining Schrödinger, Dr. Akinsanya held positions of increasing responsibility for more than a decade at Merck Research Laboratories, as Associate Director of Clinical Pharmacology driving first-in-human studies through late-stage label studies; Executive Director and therapeutic area lead in Discovery Preclinical and Early Development; and AVP of Business Development and Licensing where she managed the search and evaluation of pre-proof of concept therapeutic assets and enabling technologies as well as execution and alliance management of several significant licensing and partnering deals. Dr. Akinsanya received her B.Sc. in biochemistry from Queen Mary University of London, and her Ph.D. in endocrine physiology from the Royal Postgraduate Medical School at Imperial College in London.
Dr. Akinsanya is currently a member of the Board of Directors of the Imperial College Foundation, the Board of Trustees of The Rockefeller University, the Scientific Advisory Boards of Variant Bio and Thermo Fisher Scientific, and was previously a Scientific Advisor at CQDM. While at Merck, she provided leadership to the National Medical Fellowships to increase diversity in medicine and access to quality healthcare in underserved communities, and as Executive Ambassador to Merck For Mothers to improve maternal health in more than 30 countries. She founded My Tech Learning and served as a mentor at The Prince’s Trust to connect students to educational opportunities in science and technology.
“I’m thrilled to serve on Nautilus’ Board of Directors among renowned business leaders who have brought revolutionary innovations in the fields of genomics, cancer therapeutics, and technology to market and are now guiding an innovative approach that has enormous potential for democratizing access to proteomics for all,” commented Dr. Akinsanya. “The possibilities that Nautilus’ platform for unlocking the proteome will present are significant for the future of healthcare, from powering the discovery of breakthrough science to enabling disease diagnosis and the development of therapeutics for unmet needs with greater precision.”
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine.
For more information: https://www.nautilus.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
